Organizations
- Capricor Therapeutics
- Nippon Shinyaku
FDA extended the target date for Capricor's deramiocel application from August 22 to November 22 after accepting a major amendment. Capricor says the amendment adds 24-month HOPE-3 follow-up and analyses focused on upper-limb function. Fierce Biotech notes that the extension follows a negative advisory-committee vote on a different proposed indication and that the evidence remains contested.
What happened
- FDA accepted additional HOPE-3 follow-up and analyses as a major amendment to the deramiocel application.
- The agency extended its target action date by three months, from August 22 to November 22, 2026.
Why it matters
The extension keeps the application alive but is not an approval signal. FDA now has more time to evaluate a revised case centered on upper-limb function after advisers questioned the earlier efficacy package.
Key details
- New target date
- November 22, 2026
- Amendment
- 24-month HOPE-3 follow-up and additional analyses
- Status
- Investigational; FDA review continues
What to watch
- Whether FDA finds the revised upper-limb evidence persuasive enough to support approval.
Event chronology
How the story developed
FDA review extended
Capricor announced that FDA accepted a major amendment and moved the target decision date to November 22.
Evidence ledger
Sources behind this brief
- 01
- 02
- 03